Utility of XCL1 as a Prognostic Marker in Acute Lymphoblastic Leukemia
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of the study is to determine the utility of XCL1 in the prognosis of acute lymphoblastic leukemia.
| Condition |
|---|
|
Acute Lymphoblastic Leukemia |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Official Title: | Utility of XCL1 as a Prognostic Marker in Acute Lymphoblastic Leukemia |
- Number of patients with poor prognosis and high levels of XCL1 [ Time Frame: 3 months ] [ Designated as safety issue: No ]Number of patients with high levels of XCL1, expression of its receptor and other cytokines.
- Number of patients with poor prognosis and high levels of cytokines [ Time Frame: 3 months ] [ Designated as safety issue: No ]Measurements obtained will be evaluated to assess the prognosis of patients and made correlations with the concentration of IL-1β, IL-2 and XCL1 as well as the relationship XCR1 XCL1 and in leukemic cells.
Biospecimen Retention: Samples With DNA
whole blood, serum, white cells, blasts
| Estimated Enrollment: | 25 |
| Study Start Date: | November 2010 |
| Estimated Study Completion Date: | January 2013 |
| Estimated Primary Completion Date: | November 2012 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
|
Acute Lymphoblastic Leukemia
We will invite patients with newly diagnosed acute lymphoblastic leukemia in the Department of Hematology, who had not received anticancer therapy and regardless the subtype and immunophenotype of the disease.
|
Detailed Description:
Each year approximately 256,000 children and adults around the world develop a form of leukemia, and 209,000 died from it. Recently, some studies have evaluated the relationship between the concentration of some cytokines and prognosis of acute lymphoblastic leukemia. XCL1 is a lymphotactin that belongs to a cytokine subfamily called C or γ with only one cysteine in the N-terminal residue. It has been found with significant expression of receptor mRNA XCL1 (XCR1) in T and B lymphocytes and related to hematological neoplasms. For these reasons, XCL1 could be a efficient marker of prognosis in patients with acute lymphoblastic leukemia.
Eligibility| Ages Eligible for Study: | 1 Year and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
We will invite patients with newly diagnosed acute lymphoblastic leukemia , who had not received anticancer therapy and regardless the subtype and immunophenotype of the disease.
Inclusion Criteria:
Patients with newly diagnosed acute lymphoblastic leukemia .
Exclusion Criteria:
- Patients with prior treatment with chemotherapeutic agents.
- Patients treated with immunosuppressants.
- Patients under 12 months old.
- Patients with a diagnosis or history of autoimmune diseases.
- Patients with a diagnosis or history of immunosuppressive diseases.
- Patients who do not agree to sign a Letter of Informed Consent.
Contacts and Locations| Contact: Cesar H Gutierrez Aguirre, MD | +528183488510 | hematohu@yahoo.com |
| Contact: David Gomez Almaguer, MD | +528183488510 | dr_gomez@infosel.net.mx |
| Mexico | |
| Hospital Universitario Dr. Jose E. Gonzalez UANL | Recruiting |
| Monterrey, Nuevo Leon, Mexico, 64460 | |
| Contact: Cesar H Gutierrez Aguirre, MD +528183488510 hematohu@yahoo.com | |
| Contact: David Gomez Almaguer, MD +528183488510 dr_gomez@infosel.net.mx | |
| Principal Investigator: Cesar H Gutierrez Aguirre, MD | |
| Sub-Investigator: David Gomez, Almaguer | |
| Sub-Investigator: Juan A Flores-Jimenez, MD | |
| Principal Investigator: | Cesar H Gutierrez Aguirre, MD | Hospital Universitario Dr. Jose E. Gonzalez UANL |
More Information
Publications:
| Responsible Party: | David Gomez Almaguer MD, Hospital Universitario Dr. Jose E. Gonzalez |
| ClinicalTrials.gov Identifier: | NCT01380587 History of Changes |
| Other Study ID Numbers: | XCL1 in ALL |
| Study First Received: | June 22, 2011 |
| Last Updated: | June 23, 2011 |
| Health Authority: | Mexico: Ethics Committee |
Keywords provided by Hospital Universitario Dr. Jose E. Gonzalez:
|
ALL XCL1 Cytokines Prognosis |
Additional relevant MeSH terms:
|
Leukemia Leukemia, Lymphoid Precursor Cell Lymphoblastic Leukemia-Lymphoma Neoplasms by Histologic Type Neoplasms |
Lymphoproliferative Disorders Lymphatic Diseases Immunoproliferative Disorders Immune System Diseases |
ClinicalTrials.gov processed this record on May 23, 2013